Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 111788486 | 11178848 | 6 | F | 20150328 | 20160808 | 20150610 | 20160810 | EXP | RU-AMGEN-RUSCT2015030552 | AMGEN | 80.00 | YR | E | F | Y | 58.00000 | KG | 20160810 | MD | RU | RU |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 111788486 | 11178848 | 1 | PS | carfilzomib | CARFILZOMIB | 1 | Intravenous (not otherwise specified) | 36 MG/M2, PER CHEMO REGIM | 202714 | 36 | MG/M**2 | INTRAVENOUS INFUSION | |||||||
| 111788486 | 11178848 | 2 | SS | melphalan | MELPHALAN | 1 | Oral | 10 MG, PER CHEMO REGIM | 0 | 10 | MG | TABLET | |||||||
| 111788486 | 11178848 | 3 | SS | PREDNISONE. | PREDNISONE | 1 | Oral | 105 MG, PER CHEMO REGIM | 0 | 105 | MG | TABLET | |||||||
| 111788486 | 11178848 | 4 | C | EUTIROX | LEVOTHYROXINE SODIUM | 1 | Oral | 50 MG, QOD | 0 | 50 | MG | QD | |||||||
| 111788486 | 11178848 | 5 | C | ACICLOVIR | ACYCLOVIR | 1 | Oral | 400 MG, QD | 0 | 400 | MG | QD | |||||||
| 111788486 | 11178848 | 6 | C | BISOPROLOL | BISOPROLOL | 1 | Oral | 5 MG, BID | 0 | 5 | MG | BID | |||||||
| 111788486 | 11178848 | 7 | C | WARFARIN | WARFARIN | 1 | Oral | 2.5 MG, QOD | 0 | 2.5 | MG | QD | |||||||
| 111788486 | 11178848 | 8 | C | CEFOPERAZONE SODIUM | CEFOPERAZONE SODIUM | 1 | Intravenous (not otherwise specified) | 3 G, BID | 0 | 3 | G | BID | |||||||
| 111788486 | 11178848 | 9 | C | AMIKACIN | AMIKACIN | 1 | Intravenous (not otherwise specified) | 500 MG, BID | 2000 | MG | 0 | 500 | MG | BID | |||||
| 111788486 | 11178848 | 10 | C | AZITHROMYCIN ANHYDROUS. | AZITHROMYCIN ANHYDROUS | 1 | Oral | 500 MG, QD | 1500 | MG | 0 | 500 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 111788486 | 11178848 | 1 | Plasma cell myeloma |
| 111788486 | 11178848 | 2 | Plasma cell myeloma |
| 111788486 | 11178848 | 3 | Plasma cell myeloma |
| 111788486 | 11178848 | 4 | Hypothyroidism |
| 111788486 | 11178848 | 5 | Antiviral prophylaxis |
| 111788486 | 11178848 | 6 | Cardiac fibrillation |
| 111788486 | 11178848 | 7 | Cardiac fibrillation |
| 111788486 | 11178848 | 8 | Body temperature increased |
| 111788486 | 11178848 | 9 | Body temperature increased |
| 111788486 | 11178848 | 10 | Body temperature increased |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 111788486 | 11178848 | DE |
| 111788486 | 11178848 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 111788486 | 11178848 | Acute kidney injury |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 111788486 | 11178848 | 1 | 20140909 | 20150324 | 0 | |
| 111788486 | 11178848 | 2 | 20140909 | 20150228 | 0 | |
| 111788486 | 11178848 | 3 | 20140909 | 20150228 | 0 | |
| 111788486 | 11178848 | 4 | 201010 | 0 | ||
| 111788486 | 11178848 | 5 | 20140909 | 0 | ||
| 111788486 | 11178848 | 6 | 20141024 | 0 | ||
| 111788486 | 11178848 | 7 | 20141024 | 0 | ||
| 111788486 | 11178848 | 8 | 20150327 | 0 | ||
| 111788486 | 11178848 | 9 | 20150327 | 20150328 | 0 | |
| 111788486 | 11178848 | 10 | 20150325 | 20150327 | 0 |